Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection
Version of Record online: 29 DEC 2009
© 2010 Blackwell Publishing Ltd
Alimentary Pharmacology & Therapeutics
Volume 31, Issue 7, pages 754–759, April 2010
How to Cite
TURCO, R., MARTINELLI, M., MIELE, E., ROSCETTO, E., DEL PEZZO, M., GRECO, L. and STAIANO, A. (2010), Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection. Alimentary Pharmacology & Therapeutics, 31: 754–759. doi: 10.1111/j.1365-2036.2009.04229.x
- Issue online: 1 MAR 2010
- Version of Record online: 29 DEC 2009
- Publication data Submitted 4 November 2009 First decision 16 November 2009 Resubmitted 25 December 2009 Accepted 27 December 2009 Epub Accepted Article 29 December 2009
Aliment Pharmacol Ther 31, 754–759
Background Proton pump inhibitors (PPIs) and H2 receptor antagonists (H2RAs) may play an important role on the onset of Clostridium difficile-associated disease (CDAD) in adults. The impact of Clostridium difficile on children treated with gastric acid-suppressing agents remains unknown.
Aim To investigate the relationship between CDAD and exposure to acid suppressive therapy in hospitalized paediatric patients.
Methods We reviewed the medical records of children, with a diagnosis of protracted diarrhoea and abdominal pain, whose stool was analysed for C. difficile toxins. We identified 68 patients with CDAD. For each patient, we randomly selected one control subjects with stool analysis negative for C. difficile. Comorbid illnesses, previous hospitalizations, antibiotics, corticosteroids, immunosuppressants and gastric acid suppressing exposures were recorded.
Results The use of PPI was significantly higher in C. difficile positive group compared with C. difficile negative group [odds ratio (OR): = 4.5; 95% confidence interval (CI) = 1.4–14.4]. We also found a trend for the use of H2RAs in patients infected by C. difficile compared with C. difficile negative comparison group (OR: = 3.8; 95% CI = 0.7–18.9).
Conclusions Children exposed to PPIs therapy seem to be at higher risk for the development of Clostridium difficile-associated disease.